Terms ending in 2031
Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,710,016 | Actriib Proteins and Variants and Uses Therefore Relating to Utrophin Induction for Muscular Dystrophy Therapy In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 9,526,759 | Activin-actriia antagonists and uses for treating or preventing breast cancer In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 9,624,301 | Polynucleotides Encoding an Actriib Antibody In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 9,493,556 | Actriia Binding Agents and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.